MX352117B - Anticuerpo anti-idiotipo dirigido contra un anticuerpo dirigido contra el peptido beta amiloideo. - Google Patents

Anticuerpo anti-idiotipo dirigido contra un anticuerpo dirigido contra el peptido beta amiloideo.

Info

Publication number
MX352117B
MX352117B MX2014009062A MX2014009062A MX352117B MX 352117 B MX352117 B MX 352117B MX 2014009062 A MX2014009062 A MX 2014009062A MX 2014009062 A MX2014009062 A MX 2014009062A MX 352117 B MX352117 B MX 352117B
Authority
MX
Mexico
Prior art keywords
antibody against
amyloid
peptide
antibody
idiotype
Prior art date
Application number
MX2014009062A
Other languages
English (en)
Inventor
Stubenrauch Kay-Gunnar
Essig Ulrich
Hoesel Wolfgang
Vogel Rudolf
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX352117B publication Critical patent/MX352117B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un método para la determinación inmunológica de un anticuerpo contra el péptido amiloide ß en una muestra que utiliza un inmunoensayo empleando un anticuerpo obtenido de la línea de células DSM ACC2939, caracterizado porque le inmunoensayo comprende un anticuerpo de captación, un anticuerpo trazador y un anticuerpo de detección, en donde el anticuerpo de captación es un anticuerpo antí-idiotipo biotinilado contra un anticuerpo contra el péptido amiloido ß obtenido de la línea de célulcas DSM ACC2939 conjugado a una fase sólida vía estreptavidina, el anticuerpo trazador es un anticuerpo anti-idiotipo contra un anticuerpo contra el péptido amiloide ß obtenido de la línea de células DSM ACC 2939 conjugado a digoxigenina como marca detectable, y el anticuerpo de detección es un anticuerpo contra digoxigenina conjugado a una peroxidasa.
MX2014009062A 2008-12-22 2009-12-18 Anticuerpo anti-idiotipo dirigido contra un anticuerpo dirigido contra el peptido beta amiloideo. MX352117B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08022235 2008-12-22
PCT/EP2009/009160 WO2010072384A1 (en) 2008-12-22 2009-12-18 ANTI-IDIOTYPE ANTIBODY AGAINST AN ANTIBODY AGAINST THE AMYLOID β PEPTIDE

Publications (1)

Publication Number Publication Date
MX352117B true MX352117B (es) 2017-11-09

Family

ID=40581970

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011006641A MX2011006641A (es) 2008-12-22 2009-12-18 Anticuerpo anti-idiotipo dirigido contra un anticuerpo dirigido contra el peptido beta amiloideo.
MX2014009062A MX352117B (es) 2008-12-22 2009-12-18 Anticuerpo anti-idiotipo dirigido contra un anticuerpo dirigido contra el peptido beta amiloideo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2011006641A MX2011006641A (es) 2008-12-22 2009-12-18 Anticuerpo anti-idiotipo dirigido contra un anticuerpo dirigido contra el peptido beta amiloideo.

Country Status (22)

Country Link
US (2) US8614297B2 (es)
EP (1) EP2379601B1 (es)
JP (1) JP5642702B2 (es)
KR (2) KR20110086182A (es)
CN (2) CN106990251B (es)
AR (1) AR074816A1 (es)
AU (1) AU2009331900A1 (es)
BR (1) BRPI0923544B1 (es)
CA (1) CA2746779C (es)
CY (1) CY1118420T1 (es)
DK (1) DK2379601T3 (es)
ES (1) ES2595981T3 (es)
HR (1) HRP20161398T1 (es)
HU (1) HUE030478T2 (es)
IL (1) IL213343A0 (es)
LT (1) LT2379601T (es)
MX (2) MX2011006641A (es)
PL (1) PL2379601T3 (es)
PT (1) PT2379601T (es)
SI (1) SI2379601T1 (es)
TW (1) TWI424162B (es)
WO (1) WO2010072384A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
TW201348246A (zh) * 2012-05-21 2013-12-01 Abbvie Inc 利用蛋白質ａ親和性層析之人類、人類化或嵌合抗體之新穎純化
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3176580A1 (en) 2015-12-01 2017-06-07 Roche Diagnostics GmbH Method for reduction of interferences in immunoassays
JP6918808B2 (ja) * 2016-08-31 2021-08-11 栄研化学株式会社 異なる方式で抗原を固定化した抗原担持不溶性担体粒子を用いる抗体測定法、抗体測定用試薬
EP3969907B1 (en) * 2019-05-13 2025-09-24 F. Hoffmann-La Roche AG Interference-suppressed pharmacokinetic immunoassay
GB202410666D0 (en) * 2024-07-22 2024-09-04 Micromass Ltd Methods

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219730A (en) * 1982-09-28 1993-06-15 New York University Idiotype-anti-idiotype immunoassay
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
EP0170302A1 (fr) 1984-06-27 1986-02-05 l'Association internationale à but scientifique, dite: Institut international de pathologie cellulaire et moléculaire Procédé de dosage immunologique d'une substance dans un échantillon liquide au moyen d'anticorps anti-idiotypiques
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
EP0243471A4 (en) 1985-10-22 1989-07-11 Cooper Lipotech Inc SOLID PHASE LIPOSOME IMMUNOANALYSIS SYSTEM.
ZA898290B (en) 1988-11-03 1991-06-26 Igen Inc Electrochemiluminescent assays
US5068088A (en) 1988-11-03 1991-11-26 Igen, Inc. Method and apparatus for conducting electrochemiluminescent measurements
WO1990006515A1 (en) 1988-12-09 1990-06-14 Centocor, Inc. Anti-idiotopic immunometric assay
IL100866A (en) 1991-02-06 1995-10-31 Igen Inc Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets
DE69332377T2 (de) 1992-07-13 2003-07-03 Bionebraska, Inc. Verfahren zur modifizierung rekombinanter polypeptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
IL151378A0 (en) * 2000-02-24 2003-04-10 Univ Washington Humanized antibodies that sequester amyloid beta peptide
US7700751B2 (en) * 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
CA2451998A1 (en) * 2001-08-17 2003-02-27 Eli Lilly And Company Anti-a.beta. antibodies
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004092197A2 (en) * 2003-04-07 2004-10-28 The Regents Of The University Of California Amyloid-specific peptides and uses thereof
PE20050627A1 (es) * 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
AU2004272112A1 (en) * 2003-09-12 2005-03-24 The Regents Of The University Of California Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates
WO2005045058A2 (en) 2003-10-27 2005-05-19 Monogram Biosciences, Inc. Detecting human anti-therapeutic antibodies
US7763249B2 (en) * 2004-04-27 2010-07-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human anti-amyloid β peptide antibody and fragment of said antibody
GEP20115195B (en) * 2004-07-30 2011-04-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and use thereof
ES2396555T3 (es) * 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
PE20061323A1 (es) * 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
CN101371140B (zh) 2006-03-09 2013-11-13 弗·哈夫曼-拉罗切有限公司 抗药物抗体的测定
EP1917854A1 (en) 2006-11-06 2008-05-07 F. Hoffmann-La Roche Ag Method for producing anti idiotypic antibodies
US20080127359A1 (en) * 2006-11-06 2008-05-29 Hermann Beck Method for producing anti-idiotypic antibodies
TWI434855B (zh) * 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途

Also Published As

Publication number Publication date
SI2379601T1 (sl) 2016-11-30
BRPI0923544B1 (pt) 2021-11-23
US20100167313A1 (en) 2010-07-01
CN106990251A (zh) 2017-07-28
EP2379601A1 (en) 2011-10-26
CA2746779C (en) 2017-01-24
TWI424162B (zh) 2014-01-21
KR20130088199A (ko) 2013-08-07
ES2595981T3 (es) 2017-01-04
KR20110086182A (ko) 2011-07-27
AU2009331900A1 (en) 2010-07-01
US9547010B2 (en) 2017-01-17
WO2010072384A1 (en) 2010-07-01
IL213343A0 (en) 2011-07-31
CY1118420T1 (el) 2017-06-28
HUE030478T2 (en) 2017-05-29
US20130323762A1 (en) 2013-12-05
KR101777899B1 (ko) 2017-09-13
US8614297B2 (en) 2013-12-24
CN106990251B (zh) 2019-12-27
AR074816A1 (es) 2011-02-16
DK2379601T3 (en) 2016-08-29
JP2012513426A (ja) 2012-06-14
JP5642702B2 (ja) 2014-12-17
LT2379601T (lt) 2016-10-25
BRPI0923544A2 (pt) 2016-01-26
CN102257010A (zh) 2011-11-23
PT2379601T (pt) 2016-10-04
HRP20161398T1 (hr) 2016-12-16
PL2379601T3 (pl) 2017-02-28
TW201030335A (en) 2010-08-16
CA2746779A1 (en) 2010-07-01
MX2011006641A (es) 2011-07-12
EP2379601B1 (en) 2016-08-10

Similar Documents

Publication Publication Date Title
AR074816A1 (es) Anticuerpo anti- idiotipo dirigido contra un anticuerpo dirigido contra el peptido beta amiloide
IN2015DN00091A (es)
MX2018015933A (es) Epitopes de celulas t reguladoras, composiciones y usos para los mismos.
WO2007133822A8 (en) Gitr antibodies for the treatment of cancer
IN2012DN03338A (es)
WO2008059252A3 (en) Methods and composition fro t cell receptors which recognize 5t4 antigen
WO2007126799A3 (en) Compositions and methods of use for antibodies of c-met
CL2007003771A1 (es) Polinucleotido que codifica antigeno de n. meningitidis; vector y celula huesped que lo comprenden; polipeptido codificado; anticuerpo que se une al polipeptido; composicion que comprende el polinucleotido, vector, celula, polipeptido o anticuerpo an
MY153893A (en) Antibodies against human il17 and uses thereof
CL2011002129A1 (es) Proteinas de union a il-17; construccion de proteina de union a il-17 que comprende un polipeptido ligador o un dominio constante de una inmunoglobulina; conjugado de proteina de union a il-17; vector y celula huesped; composicion para la liberacion de una proteina de union; metodo para reducir la actividad de la il-17.
TW200639182A (en) Antibody variants and uses thereof
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
AR060017A1 (es) Composiciones y metodos de uso para anticuerpos de dickkopf -1
WO2011047087A3 (en) Protein detection via nanoreporters
NZ621170A (en) Anti-human cd52 immunoglobulins
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
EA201291065A1 (ru) Антитела против vla-4
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX2009005103A (es) Conjugado anti-idiotipo y su uso como un estandar en un inmunoensayo.
EP3483267A3 (en) Integrin alpha 8-beta 1-specific monoclonal antibody
NZ595863A (en) Antibodies to egfl7 and methods for their use
PL1987357T3 (pl) Polipeptydy rozpoznawane przez przeciwciała anty-Trichinella oraz ich zastosowanie
PH12014500384A1 (en) Anti-human xcr1 antibodies
WO2010017595A8 (en) Variant domain antibodies